UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 10, 2005
--------------------------
ARROW INTERNATIONAL, INC.
-------------------------
(Exact Name of Registrant as Specified in its Charter)
Pennsylvania 0-20212 23-1969991
----------------------------- ------------- ------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
2400 Bernville Road, Reading, Pennsylvania 19605
-------------------------------------------- ---------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (610) 378-0131
--------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
ARROW INTERNATIONAL, INC.
Item 2.02. Results of Operations and Financial Condition.
On January 10, 2005, Arrow International, Inc. issued a press release announcing
that it has reported in its Form 10-Q for its first quarter of fiscal 2005 that
it has decided to accelerate the integration of its NEOCare manufacturing
operations into its existing manufacturing structure. In order to facilitate
this integration and to address each of the inspectional observations of the
U.S. Food & Drug Administration (FDA), the Company has also decided to
temporarily cease the manufacture and shipment of its NEOCare product line,
including its NeoPICC 1.9 FR Peripherally Inserted Central Catheters (the
"NeoPICC Catheters") for which it has recently initiated a voluntary nationwide
recall. As a result of this recall, the Company also announced that it has
recorded a charge of $500,000 for estimated sales credits relating to the
NeoPICC Catheters and has adjusted its previously announced net sales and net
income results for the fiscal quarter ended November 30, 2004 accordingly.
A copy of this press release is attached to this report as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
EXHIBIT NUMBER DESCRIPTION
99.1 Press release dated January 10, 2005 issued by Arrow
International, Inc.
ARROW INTERNATIONAL, INC.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ARROW INTERNATIONAL, INC.
Date: January 11, 2005 By: /s/ Frederick J. Hirt
----------------------------------
Frederick J. Hirt
Chief Financial Officer and
Senior Vice President-Finance
(Principal Financial Officer and
Chief Accounting Officer)
EXHIBIT INDEX
EXHIBIT DESCRIPTION METHOD OF FILING
NUMBER OF EXHIBIT
99.1 Press Release dated January 10, 2005, Furnished herewith.
issued by Arrow International, Inc.